Ampio Pharmaceuticals Announces Initiation Of Phase II Clinical Trial Of Optina™
Ampio Pharmaceuticals Announces Initiation Of Phase II Clinical Trial Of Optina™
Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE) announced the initiation of a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus. Ampio Pharmaceuticals has completed a formal agreement with St Michael’s Hospital, Toronto, Canada …
Read more on Medical News Today
Related posts:
- Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME
- Clinical trial for diabetic macular edema enrolling patients
- Amylin Pharmaceuticals to Present New Data and Insights From the Company’s Diabetes Programs at ADA 2010
- Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis
- InNexus Announces Discovery Of Novel Protein For AMD Eye Disorder - Will Bypass Needles With Topical Application